The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation

Yuan, Yan; Du, Yang; Wang, Lei; Liu, Xiuheng

doi:10.7150/jca.42338



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(12):3588-3595. doi:10.7150/jca.42338 This issue Cite

Research Paper

The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation

Yan Yuan, Yang Du, Lei Wang, Xiuheng Liu^✉

Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, P.R. China.

Citation:

Yuan Y, Du Y, Wang L, Liu X. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer 2020; 11(12):3588-3595. doi:10.7150/jca.42338. https://www.jcancer.org/v11p3588.htm

Other styles

Abstract

N6-methyladenosine (m⁶A) is the richest modification in mammalian messenger RNAs (mRNAs), and exerts key roles in many biological processes, including cancer development, whereas its roles in prostate carcinoma (PCa) remain to be unclear. Here, we found that m⁶A modifications are increased in PCa and methyltransferase-like 3 (METTL3), but not other major m⁶A modification genes including METTL14, fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5), was the major dysregulated gene associated with abnormal m⁶A modification. In addition, METTL3 up-regulation acted as a poor prognostic factor for overall survival and disease-free survival in PCa patients. Knockdown of METTL3 significantly inhibited PCa cells proliferation, migration, and invasion. In addition, over-expression of METTL3, but not its catalytic mutant form, significantly promoted PCa cells growth and progression. Mechanistically, we revealed that METTL3 enhanced MYC(c-myc) expression by increasing m⁶A levels of MYC mRNA transcript, leading to oncogenic functions in PCa. Importantly, PCa cells growth and progression inhibition by METTL3 knockdown were restored through over-expression of MYC. Our results uncovered a METTL3/m⁶A/MYC axis and provided insight into the mechanisms of PCa progression.

Keywords: N6-methyladenosine, prostate carcinoma, METTL3, MYC

Citation styles

APA

Yuan, Y., Du, Y., Wang, L., Liu, X. (2020). The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. Journal of Cancer, 11(12), 3588-3595. https://doi.org/10.7150/jca.42338.

ACS

Yuan, Y.; Du, Y.; Wang, L.; Liu, X. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J. Cancer 2020, 11 (12), 3588-3595. DOI: 10.7150/jca.42338.

NLM

CSE

Yuan Y, Du Y, Wang L, Liu X. 2020. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer. 11(12):3588-3595.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.